Skip to Content

Levodopa Pregnancy and Breastfeeding Warnings

Levodopa is also known as: Dopar, Larodopa

Levodopa Pregnancy Warnings

Levodopa has not been formally assigned to a pregnancy category. However, some of the commercially available formulations of levodopa-carbidopa have been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of visceral and skeletal malformations in rabbits at doses 5 to 20 times the maximum recommended human dose of levodopa-carbidopa. There are no controlled data in human pregnancy. Two reports have described three patients who received levodopa or levodopa-carbidopa throughout pregnancy without evidence of fetal harm. Levodopa should only be given in human pregnancy when benefit outweighs risk.

One study has reported that single oral doses of levodopa administered to pregnant women result in decreased plasma renin activity, decreased plasma aldosterone and decreased plasma prolactin.

See references

Levodopa Breastfeeding Warnings

There are no data on the excretion of levodopa into human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
  2. "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.

References for breastfeeding information

  1. "Product Information. Larodopa (levodopa)." Roche Laboratories, Nutley, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.